<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17530" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Acute Anemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Killeen</surname>
            <given-names>Robert B.</given-names>
          </name>
          <aff>University of Illinois</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tambe</surname>
            <given-names>Ajay</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Robert Killeen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ajay Tambe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17530.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Acute anemia is a critical condition characterized by a rapid decrease in red blood cell count, leading to impaired oxygen delivery to tissues and organs. This can result from sudden blood loss due to trauma, hemorrhage, or hemolysis, necessitating immediate intervention to stabilize the patient's condition and address the underlying cause. Effective management requires prompt recognition, accurate diagnosis, and timely implementation of resuscitative measures to restore adequate tissue perfusion and prevent further complications. Collaboration among healthcare professionals from various specialties is essential to optimize patient care and outcomes in acute anemia cases.</p>
        <p>This activity allows healthcare professionals to stay abreast of the latest advancements in the diagnosis, management, and collaborative care of acute anemia. Participants will enhance their knowledge and skills in differentiating etiologies, implementing resuscitation measures, and applying evidence-based guidelines. Additionally, this activity aims to foster effective collaboration with specialists in hematology/oncology, gastroenterology, and surgery to provide comprehensive care to patients with acute anemia. By improving healthcare providers' competence and coordination, this activity enhances patient outcomes and mitigates the healthcare burden associated with acute anemia.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify different etiologies of acute anemia based on clinical presentation, laboratory findings, and patient history.</p></list-item><list-item><p>Implement resuscitation measures promptly for patients with acute anemia following the ABC ( (airway, breathing, circulation) approach as indicated based on the severity of anemia and the underlying cause.</p></list-item><list-item><p>Apply evidence-based guidelines for managing acute anemia, including appropriate use of blood products, pharmacological interventions, and referral to specialist care when necessary.</p></list-item><list-item><p>Collaborate with other healthcare professionals, including specialists in hematology/oncology, gastroenterology, and surgery, to provide comprehensive care for patients with acute anemia and address their unique needs.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17530&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17530">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17530.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Anemia&#x000a0;is characterized by a deficiency in the number of circulating red blood cells (RBCs), the amount of hemoglobin, or the volume of packed RBCs, known as hematocrit.<xref ref-type="bibr" rid="article-17530.r1">[1]</xref>&#x000a0;The&#x000a0;World Health Organization (WHO) defines anemia as a hemoglobin level&#x000a0;below 13 g/dL in men and&#x000a0;below 12 g/dL in women.<xref ref-type="bibr" rid="article-17530.r2">[2]</xref>&#x000a0;</p>
        <p>Anemia can be classified into 2 main types:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acute</bold> anemia&#x000a0;involves a sudden and rapid&#x000a0;decrease in RBCs,&#x000a0;typically caused by hemolysis or acute hemorrhage.</p>
          </list-item>
          <list-item>
            <p><bold>Chronic</bold> anemia is characterized by a gradual decline in RBCs over time.&#x000a0;Its&#x000a0;causes are&#x000a0;varied&#x000a0;and&#x000a0;may include conditions such as iron or other nutritional deficiencies, chronic diseases, drug-induced factors,&#x000a0;and other&#x000a0;underlying health issues.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17530.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Anemia can&#x000a0;result from&#x000a0;various events and underlying conditions. Blood loss is among the most prevalent causes, resulting in&#x000a0;decreased RBCs. This occurrence is widespread in cases of acute anemia&#x000a0;observed in emergency room settings. Emergent conditions leading to acute anemia include traumatic injury causing&#x000a0;arterial bleeding, ruptured aneurysms, massive upper or lower gastrointestinal (GI) hemorrhages,&#x000a0;ruptured ectopic pregnancies, and&#x000a0;disseminated intravascular coagulation (DIC).</p>
        <p>Hemolytic anemias can also&#x000a0;contribute to acute&#x000a0;and chronic anemia,&#x000a0;characterized by the destruction&#x000a0;or reduced survival of RBCs. They are typically classified into 2 main categories: intracorpuscular and extracorpuscular.&#x000a0;</p>
        <p><bold>Intracorpuscular</bold>&#x000a0;<bold>Hemolytic Anemias</bold></p>
        <p>Intracorpuscular hemolytic anemias encompass conditions where the defect or issue&#x000a0;originates within the&#x000a0;RBC itself. These abnormalities can involve defects in the RBC's membrane, enzymes, or hemoglobin molecules, leading to premature cell breakdown and subsequent anemia.</p>
        <p><bold>Hemoglobinopathies</bold> affect the structure or function of hemoglobin.</p>
        <list list-type="bullet">
          <list-item>
            <p>Sickle cell disease arises from a point mutation in the beta-globin chain's DNA, producing abnormal hemoglobin&#x000a0;known as hemoglobin S (Hgb S). Under oxidative stress conditions, the Hgb S molecules polymerize and cause the RBCs to assume a sickle shape, which is less flexible and can block blood vessels, leading to tissue damage, pain crises, and other complications.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Thalassemias&#x000a0;involve&#x000a0;reduced alpha or beta globin chain production, leading to imbalanced&#x000a0;hemoglobin synthesis. Due to the abnormal structure or function of hemoglobin, these conditions can cause various complications, including tissue damage and pain crises.&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Enzymopathies</bold>&#x000a0;refer to conditions characterized by&#x000a0;abnormalities in specific enzymes within RBCs (see <bold>Table.&#x000a0;</bold>Enzymopathies Causing Hemolytic Anemia).&#x000a0;These enzyme defects can disrupt normal cellular processes and lead to various clinical manifestations, including hemolysis and anemia.</p>
        <table-wrap id="article-17530.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1.&#x000a0;Enzymopathies Causing Hemolytic Anemia</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">
<bold>Hemolytic Anemia Condition</bold>
</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<bold>Abnormality</bold>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Glucose-6-phosphate dehydrogenase (G6PD) deficiency</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>X-linked</p></list-item><list-item><p>Affects pentose pathway</p></list-item><list-item><p>Hemolysis is often triggered by external factors such as certain medications, infections, or exposure to oxidative stress</p></list-item></list>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Hemophilia A</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>X-linked</p></list-item><list-item><p>Factor VIII deficiency</p></list-item><list-item><p>Causes prolonged&#x000a0;bleeding after injuries or surgeries.</p></list-item></list>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Pyruvate kinase (PK) deficiency</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Autosomal recessive</p></list-item><list-item><p>Deficiency of the PK enzyme</p></list-item><list-item><p>Leads to nonspherocytic anemia</p></list-item></list>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">
<p>Phosphofructokinase (PFK) deficiency</p>
<p>(Known as Glycogen storage disease or Glycogenesis Type VII)</p>
</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Autosomal Recessive</p></list-item><list-item><p>Deficiency of PFK</p></list-item><list-item><p>May experience muscle pain, rhabdomyolysis, and hemolytic anemia</p></list-item></list>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Phosphoglycerate kinase (PGK) deficiency</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>X-linked&#x000a0;</p></list-item><list-item><p>Deficiency of PGK enzyme</p></list-item><list-item><p>Causes myopathy, splenomegaly,&#x000a0;central nervous system disturbances</p></list-item><list-item><p>Leads to nonspherocytic hemolytic anemia</p></list-item></list>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Aldolase deficiency</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Autosomal recessive</p></list-item><list-item><p>Deficiency of aldolase enzyme</p></list-item><list-item><p>Causes muscle weakness</p></list-item></list>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Triosephosphate isomerase (TPI) deficiency</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Autosomal recessive</p></list-item><list-item><p>Various symptoms:&#x000a0;anemia, intellectual disability, cardiomyopathy, and increased susceptibility to infections</p></list-item></list>
</td>
              </tr>
              <tr style="height: 13.5px;">
                <td style="height: 13.5px;" rowspan="1" colspan="1">
<p>Membrane-cytoskeletal defects</p>
<list list-type="bullet"><list-item><p>Hereditary spherocytosis</p></list-item><list-item><p>Hereditary elliptocytosis</p></list-item></list>
</td>
                <td style="height: 13.5px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Affects the RBC membrane and cytoskeleton</p></list-item><list-item><p>Result in the disfigurement of RBCs, leading to the removal of the spleen&#x000a0;<xref ref-type="bibr" rid="article-17530.r3">[3]</xref><xref ref-type="bibr" rid="article-17530.r4">[4]</xref><xref ref-type="bibr" rid="article-17530.r5">[5]</xref>&#x000a0;</p></list-item></list>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">
<p>Paroxysmal nocturnal hemoglobinuria (PNH)</p>
</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Acquired&#x000a0;disorder</p></list-item><list-item><p>Clonal autoimmune mechanism that leads to hemolysis, thrombosis, and marrow aplasia</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Extracorpuscular Hemolytic Anemias</bold>
</p>
        <p>Extracorpuscular hemolytic anemias are a group of disorders where the defect leading to RBC destruction originates outside the RBC itself.&#x000a0;These conditions typically involve factors in the bloodstream or external to the&#x000a0;RBCs that cause their premature destruction.</p>
        <p>
<bold>Mechanical destruction (microangiopathic):</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Thrombotic thrombocytopenic purpura (TTP) is characterized by the formation of platelet-rich thrombi in small blood vessels, primarily caused by a deficiency in ADAMTS13, metalloprotease responsible for cleaving von Willebrand factor. The classic triad&#x000a0;of TTP includes microangiopathic hemolytic anemia, severe thrombocytopenia, and organ ischemia.<xref ref-type="bibr" rid="article-17530.r6">[6]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Familial (atypical) hemolytic-uremic syndrome (HUS) results from gene mutations encoding complement regulatory proteins, leading to complement system dysregulation, immune system activation, and damage to small blood vessels.&#x000a0;HUS also presents with a triad of&#x000a0;microangiopathic hemolytic anemia, thrombocytopenia, and renal failure, though its lesions are primarily confined to the kidneys, distinguishing it from TTP.<xref ref-type="bibr" rid="article-17530.r7">[7]</xref><xref ref-type="bibr" rid="article-17530.r8">[8]</xref><xref ref-type="bibr" rid="article-17530.r7">[7]</xref></p>
          </list-item>
        </list>
        <p><bold>Complement-mediated thrombotic microangiopathy </bold>is defined&#x000a0;by the abnormal activation of the complement system,&#x000a0;resulting&#x000a0;in the formation of small blood clots&#x000a0;within the microvasculature. This&#x000a0;phenomenon can manifest&#x000a0;in various disorders, including HUS.</p>
        <p><bold>Immune thrombocytopenic purpura</bold>&#x000a0;is a&#x000a0;condition in which&#x000a0;IgG autoantibodies&#x000a0;bind&#x000a0;to platelets, marking them for destruction by the spleen.&#x000a0;Consequently, platelet count decreases, raising the risk of bleeding, particularly when platelet levels plummet significantly.</p>
        <p><bold>Disseminated intravascular coagulation</bold>&#x000a0;is characterized&#x000a0;by widespread systemic activation of coagulation&#x000a0;throughout the body&#x000a0;in response to various underlying causes, such as infections, severe trauma, or certain complications during pregnancy. DIC&#x000a0;results in excessive formation of intravascular fibrin, causing thrombosis. However, as coagulation factors are consumed, bleeding complications can arise.<xref ref-type="bibr" rid="article-17530.r9">[9]</xref></p>
        <p><bold>Toxic agents and drugs</bold> can destroy RBCs and cause hemolysis. Exposure&#x000a0;to substances such as hyperbaric oxygen (or 100% oxygen), certain medications (eg, methyldopa, nitrates, chlorates, methylene blue, dapsone, cisplatin), numerous aromatic (cyclic) compounds, and other chemicals (arsine, stibine, copper, and lead) can&#x000a0;trigger this process.</p>
        <p><bold>Infectious</bold> causes of hemolytic anemia include malaria, the most prevalent worldwide, and in certain regions, infection with Shiga toxin-producing E. Coli O157:H7, which leads to&#x000a0;HUS.&#x000a0;Additionally, in specific clinical situations such as open wounds, septic abortion, or contaminated blood transfusions, <italic toggle="yes">Clostridium perfringens</italic> sepsis can induce life-threatening hemolysis&#x000a0;through&#x000a0;the action of a toxin with lecithinase activity.</p>
        <p><bold>Autoimmune hemolytic anemia</bold>&#x000a0;occurs when IgG antibodies target and bind to RBCs, leading to their destruction by macrophages, resulting in hemolysis. The affected RBCs often assume a rigid and nonelastic spherical shape known as spherocytes, making them more prone to rapid destruction. This type of anemia can be associated with autoimmune diseases (eg, lupus), certain types of lymphomas and leukemias,&#x000a0;or can be drug-induced. In many cases, the cause remains unidentified.<xref ref-type="bibr" rid="article-17530.r10">[10]</xref></p>
        <p><bold>Hypersplenism</bold> is characterized by&#x000a0;splenomegaly, resulting in increased destruction of blood cells, including RBCs. In acute conditions, such as infections or other causes of hemolysis, the spleen removes more RBCs,&#x000a0;exacerbating the loss.<xref ref-type="bibr" rid="article-17530.r11">[11]</xref>&#x000a0;When the rate of hypersplenic destruction&#x000a0;surpasses the marrow's capacity to&#x000a0;produce&#x000a0;RBCs, the anemia becomes more severe.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-17530.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Anemia is a&#x000a0;prevalent condition, affecting one-fourth of the&#x000a0;general population.&#x000a0;Its prevalence is even higher among hospitalized patients, with approximately 50% affected. Among&#x000a0;older hospitalized patients, the rate of anemia can&#x000a0;rise to as high as&#x000a0;75%.&#x000a0;</p>
        <p>Data collected in 2000&#x000a0;from over 81,000 health plan members revealed&#x000a0;varying rates of anemia across specific patient populations. Patients with chronic kidney disease exhibited the highest prevalence of anemia,&#x000a0;at 34.5%.&#x000a0;Anemia prevalence among patients with cancer was 21%, while those with chronic heart disease had a rate of 18%. Inflammatory bowel disease accounted for 13% of anemia cases, followed by rheumatoid arthritis at 10%.&#x000a0;Additionally, individuals with HIV infection had a 10% prevalence of anemia.<xref ref-type="bibr" rid="article-17530.r12">[12]</xref>&#x000a0; &#x000a0;</p>
      </sec>
      <sec id="article-17530.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Acute anemia&#x000a0;typically arises from&#x000a0;2 common causes: hemolysis or hemorrhage, both of which lead to a sudden&#x000a0;decrease&#x000a0;in RBCs. When the&#x000a0;decline in RBCs is rapid, a hemoglobin level of 7 to 8 g/dL often triggers symptoms, as the body has insufficient time to compensate and replenish the lost volume. Healthy individuals can typically tolerate up to a 20% loss of blood volume without significant symptoms due to reflex vasospasm and the redistribution of blood flow.</p>
        <p>However, when blood loss&#x000a0;surpasses this&#x000a0;threshold, patients&#x000a0;start exhibiting&#x000a0;signs and symptoms of hypovolemia. Compensatory mechanisms, like the redistribution of blood flow, become inadequate to&#x000a0;sustain blood pressure,&#x000a0;resulting&#x000a0;in clinical&#x000a0;manifestations such as postural hypotension, altered mental status, cool and clammy skin, tachycardia, and hyperventilation.</p>
        <p>In cases of acute hemorrhage,&#x000a0;hemoglobin and hematocrit levels&#x000a0;may initially&#x000a0;appear normal because both RBCs and plasma are lost concomitantly. This&#x000a0;discrepancy becomes evident once&#x000a0;intravenous fluids&#x000a0;restore or replenish the patient&#x02019;s plasma volume.</p>
      </sec>
      <sec id="article-17530.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>When examining a peripheral blood smear under a microscope, specific findings can provide valuable&#x000a0;insights&#x000a0;into the underlying condition. Observations related to certain types of anemia are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Microangiopathic hemolysis: In conditions characterized by microangiopathic hemolysis, such as TTP, immune thrombocytic purpura (ITP), HUS, and DIC, a peripheral blood smear examination may reveal several abnormal RBC shapes. These abnormalities include&#x000a0;helmet cells (schistocytes), fragmented RBCs, and other RBC fragments. Spherocytes (small, round RBCs lacking central pallor)&#x000a0;may also be&#x000a0;present in some cases.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sickle cell disease:&#x000a0;A hallmark finding in&#x000a0;sickle cell disease is the presence of sickle-shaped cells, also known as sickle cells. These cells have a crescent or "sickle" shape due to the abnormal Hgb S in individuals with this genetic disorder. Another characteristic feature of sickle cell disease is Howell-Jolly bodies, which are small nuclear remnants within RBCs. Howell-Jolly bodies are typically seen in individuals with functional asplenia or hyposplenism.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17530.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>When evaluating a patient with anemia, obtaining a&#x000a0;comprehensive yet&#x000a0;focused medical history is essential for guiding further assessment and management. However, specific priorities should be addressed initially,&#x000a0;including managing the patient's&#x000a0;airway, breathing, and circulation (ABCs) are stable. If required, immediate resuscitation measures should be initiated to stabilize the patient.</p>
        <p>In&#x000a0;situations where the patient cannot communicate, obtaining as much information as possible from emergency medical services (EMS) personnel or individuals at the bedside is crucial. Additionally, reviewing previous medical charts, if available, can&#x000a0;offer valuable insights into the patient's medical history and&#x000a0;aid in understanding the underlying cause of anemia.</p>
        <p>A focused history should also include&#x000a0;identifying the potential source of bleeding. For example, if GI hemorrhage is suspected,&#x000a0;obtaining a&#x000a0;detailed GI history is essential, which may involve asking about any prior episodes of GI bleeding, symptoms of GI disorders, or known GI conditions. Similarly, if gynecological causes are suspected, a focused menstrual and pregnancy history should be taken to evaluate any potential gynecological sources of bleeding.</p>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>In&#x000a0;assessing a patient with anemia,&#x000a0;regular monitoring of vital signs is essential to&#x000a0;evaluate the patient's stability and response to interventions. As mentioned earlier, the initial physical examination should focus on the organ or system suspected to be the source of bleeding. If trauma is suspected, a thorough examination of the chest, abdomen, pelvis, and extremities is necessary, including assessing for signs of injury. Additionally, imaging studies may be&#x000a0;conducted as clinically indicated to further evaluate potential injuries or sources of bleeding.&#x000a0;</p>
        <p>The presentation of hemorrhagic shock can be categorized into different stages based on the amount of blood loss and the associated clinical signs. The various stages typically include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Class 1 (&#x0003c;15% blood loss):
<list list-type="bullet"><list-item><p>Mild tachycardia&#x000a0;is usually the first sign</p></list-item><list-item><p>Blood pressure remains within normal range</p></list-item><list-item><p>The skin may start to feel cool to the touch</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Class 2 (15%-30% blood loss):
<list list-type="bullet"><list-item><p>Tachycardia continues, becoming more pronounced</p></list-item><list-item><p>Tachypnea begins</p></list-item><list-item><p>Pulse pressure decreases</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Class 3 (30%-40% blood loss):
<list list-type="bullet"><list-item><p>Tachycardia worsens, with a rapid and weak pulse</p></list-item><list-item><p>The decrease in blood pressure&#x000a0;becomes more significant</p></list-item><list-item><p>Skin becomes cold and appears pale and mottled</p></list-item><list-item><p>Urine output decreases significantly</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Class 4 (&#x0003e;40% blood loss):
<list list-type="bullet"><list-item><p>This stage is dangerous&#x000a0;and carries a high mortality rate</p></list-item><list-item><p>Tachycardia and decreased blood pressure continue to worsen&#x000a0;and can lead to loss of consciousness</p></list-item><list-item><p>The pulse can disappear if there is &#x0003e;50% blood loss</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Additional findings during a skin examination can offer valuable insights into assessing a patient with potential bleeding disorders or hemorrhage. These may include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Flank ecchymosis (Grey-Turner sign):&#x000a0;Bruising in the flank area can indicate retroperitoneal hemorrhage.</p>
          </list-item>
          <list-item>
            <p>Umbilical ecchymosis (Cullen sign): The appearance of bruising around the umbilicus can suggest intraperitoneal or retroperitoneal bleeding.</p>
          </list-item>
          <list-item>
            <p>Jaundiced, yellow skin: Jaundice can indicate liver disease, certain hemoglobinopathies, or other forms of hemolysis.</p>
          </list-item>
          <list-item>
            <p>Purpura and petechiae:&#x000a0;The presence of purpura or petechiae can suggest platelet disorders or abnormalities in blood clotting.</p>
          </list-item>
          <list-item>
            <p>Hemarthrosis: Bleeding&#x000a0;into joint spaces can indicate a bleeding disorder such as hemophilia.</p>
          </list-item>
          <list-item>
            <p>Diffuse bleeding from intravenous sites and mucous membranes:&#x000a0;This may be a sign of DIC.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17530.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A further diagnostic workup is crucial to determining the etiology and severity of the bleeding. This comprehensive assessment may include a range of tests and procedures to identify the underlying cause and extent of the hemorrhage.</p>
        <p>Blood typing and cross-matching involve promptly sending a blood sample to the laboratory for typing and cross-matching. This facilitates the preparation of blood products if transfusion is necessary, ensuring&#x000a0;compatibility and safety during transfusion procedures.&#x000a0;</p>
        <p>Complete blood count (CBC) provides essential&#x000a0;insights into&#x000a0;the patient's&#x000a0;RBC count, hemoglobin, and hematocrit levels, aiding&#x000a0;in evaluating blood loss and the severity of anemia. However, it is essential to&#x000a0;recognize&#x000a0;that in actively bleeding patients, the initial hematocrit level may not accurately reflect the true extent of blood loss due to temporary dilutional effects&#x000a0;maintaining&#x000a0;normal levels.</p>
        <p>Serial CBC monitoring is&#x000a0;crucial in acute bleeding cases, as it allows for tracking changes in&#x000a0;hemoglobin&#x000a0;and hematocrit levels over time. This ongoing assessment helps clinicians gauge the effectiveness of interventions and the patient's response to treatment.</p>
        <p>Mean corpuscular volume (MCV) is a valuable parameter&#x000a0;used to classify anemia into different types based on the average volume of RBCs.</p>
        <list list-type="bullet">
          <list-item>
            <p>Microcytic anemias (MCV &#x0003c;80 fL) are&#x000a0;identified by small RBCs. The mnemonic TAILS can help assist in recalling&#x000a0;the common causes:
<list list-type="bullet"><list-item><p>Thalassemia</p></list-item><list-item><p>Anemia of chronic disease</p></list-item><list-item><p>Iron deficiency anemia</p></list-item><list-item><p>Lead poisoning</p></list-item><list-item><p>Sideroblastic anemia/sickle cell disease</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Normocytic anemias (MCV 80 to 100 fL) feature normal-sized RBCs. Causes encompass:
<list list-type="bullet"><list-item><p>Active bleeding</p></list-item><list-item><p>Anemia of chronic disease</p></list-item><list-item><p>Hemolysis</p></list-item><list-item><p>Malignancy</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Macrocytic anemias (MCV &#x0003e;100 fL)&#x000a0;exhibit&#x000a0;large RBCs. Causes include:
<list list-type="bullet"><list-item><p>Alcohol-related anemia</p></list-item><list-item><p>Folate deficiency</p></list-item><list-item><p>Vitamin B-12 deficiency</p></list-item><list-item><p>Some preleukemic conditions</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Lactate dehydrogenase (LDH), haptoglobin, and bilirubin&#x000a0;can indicate hemolytic anemia with elevated LDH and indirect bilirubin levels and decreased haptoglobin levels.</p>
        <p>Blood urea nitrogen (BUN) levels are commonly elevated in patients with upper GI bleeds due to undigested blood.</p>
        <p>Reticulocyte count is&#x000a0;increased due to an erythropoietic response by the bone marrow, suggesting active RBC production. Conversely, a low reticulocyte count may&#x000a0;indicate an inadequate bone marrow response, as seen in conditions such as aplastic anemia, hematologic cancers, drugs, or toxins. Reticulocytosis&#x000a0;often corresponds&#x000a0;with an increased MCV in the blood count.</p>
        <p>Screening labs for DIC typically include prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, fibrin split products, and platelet count.&#x000a0;Diagnostic findings indicative of DIC comprise&#x000a0;increased coagulation times, decreased platelets and fibrinogen levels, and fibrin split products. DIC should be considered in the diagnosis of patients experiencing severe sepsis, childbirth complications, burns, malignancies, or&#x000a0;uncontrolled hemorrhage.</p>
        <p>Additional studies for evaluating anemia include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Folate and vitamin B12 levels</p>
          </list-item>
          <list-item>
            <p>Lead levels</p>
          </list-item>
          <list-item>
            <p>Hemoglobin electrophoresis</p>
          </list-item>
          <list-item>
            <p>Factor deficiency tests</p>
          </list-item>
          <list-item>
            <p>Bleeding time</p>
          </list-item>
          <list-item>
            <p>Bone marrow aspiration</p>
          </list-item>
          <list-item>
            <p>Coombs test</p>
          </list-item>
        </list>
        <p>Imaging studies&#x000a0;are vital for assessing anemia and identifying the source of bleeding. Common imaging modalities and procedures used for this purpose include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ultrasound: A quick and noninvasive&#x000a0;tool&#x000a0;for diagnosing intraperitoneal bleeding. In trauma settings, a focused abdominal sonography for trauma (FAST) examination is often performed to assess for intraabdominal hemorrhage, especially in unstable patients.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chest x-ray: Helpful in trauma patients to identify potential sources of bleeding such as hemothorax, pulmonary contusions, aortic rupture, or free air under the diaphragm associated with&#x000a0;GI bleeding.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Computed tomography scanning: Beneficial in patients with&#x000a0;GI trauma or suspected GI bleeding.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Esophagogastroduodenoscopy: Commonly employed for&#x000a0;diagnostic and therapeutic purposes in cases of upper GI bleeding.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sigmoidoscopy or colonoscopy: Valuable tools for diagnosing and sometimes treating lower GI bleeding.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17530.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment and management of acute anemia are paramount in stabilizing the patient and addressing the condition's underlying cause. Acute anemia requires prompt intervention to restore adequate oxygen delivery to tissues and prevent further complications. Treatment strategies often involve a combination of measures aimed at stopping ongoing bleeding, replacing lost blood volume, and addressing the underlying cause of the anemia.&#x000a0;</p>
        <p>
<bold>Initial Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Evaluate the ABCs (airway, breathing, and circulation)</p>
          </list-item>
          <list-item>
            <p>Treat any life-threatening conditions immediately</p>
          </list-item>
          <list-item>
            <p>Administer supplemental oxygen</p>
          </list-item>
          <list-item>
            <p>Establish&#x000a0;2&#x000a0;large-bore intravenous lines</p>
          </list-item>
          <list-item>
            <p>Intravenous&#x000a0;fluid resuscitation (crystalloid is the initial fluid of choice)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Apply direct pressure to any hemorrhage if possible&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Treatment&#x000a0;</bold>
</p>
        <p>The primary treatment for acute anemia involves&#x000a0;administering&#x000a0;packed red blood cells (pRBCs) to&#x000a0;replenish the lost blood volume.&#x000a0;Typically, each unit of pRBCs is expected to increase the hematocrit by approximately 3 points.</p>
        <p>
<bold>Transfusion thresholds</bold>
</p>
        <p>A restrictive transfusion strategy is generally followed for hospitalized, hemodynamically stable adult patients,&#x000a0;those in critically care settings, with transfusion not recommended&#x000a0; until the&#x000a0;hemoglobin concentration drops to 7 g/dL or lower.<xref ref-type="bibr" rid="article-17530.r13">[13]</xref>&#x000a0;However, in patients with acute coronary syndrome, transfusion&#x000a0;consideration arises when&#x000a0;hemoglobin level equals or falls below 8 g/dL.<xref ref-type="bibr" rid="article-17530.r14">[14]</xref></p>
        <p>For actively bleeding patients, transfusion decisions should be guided by clinical&#x000a0;context and bleeding severity, with a more liberal approach&#x000a0;potentially required to&#x000a0;maintain hemodynamic stability&#x000a0;during ongoing hemorrhage until bleeding control is achieved. In cases of massive hemorrhages, such as trauma or major surgical procedures, initiation of a massive transfusion protocol is warranted. This protocol involves&#x000a0;promptly administering blood products, including pRBCs, fresh frozen plasma (FFP), platelets, and sometimes cryoprecipitate, to&#x000a0;ensure hemodynamic stability and&#x000a0;replenish coagulation factors.</p>
        <p>All these blood components are integral to treating specific conditions associated with anemia. They may be considered in instances as outlined (see <bold>Table.&#x000a0;</bold>Treatment Options for Acute Anemia):&#x000a0;</p>
        <table-wrap id="article-17530.table1" position="float" orientation="portrait">
          <caption>
            <title>Table 2. Treatment Options for Acute Anemia</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr>
                <td style="width: 93.125px;" rowspan="1" colspan="1">
<bold>Blood Product</bold>
</td>
                <td style="width: 216.875px;" rowspan="1" colspan="1">
<bold>Indication</bold>
</td>
              </tr>
              <tr>
                <td style="width: 93.125px;" rowspan="1" colspan="1">Platelets</td>
                <td style="width: 216.875px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Thrombocytopenia or platelet dysfunction</p></list-item><list-item><p>Typically administered to prevent or control bleeding in patients with&#x000a0;significant&#x000a0;platelet deficiencies</p></list-item><list-item><p>Each unit of platelets raises the platelet count by approximately 10,000 microliters</p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 93.125px;" rowspan="1" colspan="1">Fresh frozen plasma (FFP)</td>
                <td style="width: 216.875px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Blood products that contain all the coagulation factors</p></list-item><list-item><p>Replenishes depleted clotting factors in patients&#x000a0;with&#x000a0;coagulopathies</p></list-item><list-item><p>Rapidly corrects coagulation abnormalities</p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 93.125px;" rowspan="1" colspan="1">Cryoprecipitate</td>
                <td style="width: 216.875px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Rich in fibrinogen, factor VIII, von Willebrand factor (vWF), factor XIII</p></list-item><list-item><p>Hemophilia A, von Willebrand disease, fibrinogen deficiency</p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 93.125px;" rowspan="1" colspan="1">
<bold>Pharmacologic Options</bold>
</td>
                <td style="width: 216.875px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
              <tr>
                <td style="width: 93.125px;" rowspan="1" colspan="1">&#x000a0;Vasopressors</td>
                <td style="width: 216.875px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Norepinephrine,&#x000a0;dopamine</p></list-item><list-item><p>Increase blood pressure and cause vasoconstriction&#x000a0;</p></list-item><list-item><p>Used to manage hypovolemic shock and conditions with significant blood loss</p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 93.125px;" rowspan="1" colspan="1">
<p>&#x000a0;Gastric acid inhibitors&#x000a0;</p>
<p>(H2-receptor antagonists)</p>
</td>
                <td style="width: 216.875px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Ranitidine, famotidinene</p></list-item><list-item><p>Reduce gastric acid secretion</p></list-item><list-item><p>Aid in healing gastric and duodenal ulcers</p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 93.125px;" rowspan="1" colspan="1">Glucocorticoid medications&#x000a0;</td>
                <td style="width: 216.875px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Prednisone</p></list-item><list-item><p>Treat autoimmune hemolytic anemias</p></list-item><list-item><p>Help suppress the immune response and decrease the destruction of RBCs&#x000a0;</p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 93.125px;" rowspan="1" colspan="1">Vitamin K</td>
                <td style="width: 216.875px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Administered to patients with liver disease or on certain medications such as anticoagulants to correct coagulation abnormalities</p></list-item><list-item><p>Replenishes vitamin K-dependent clotting factors, including factors VII, IX, and X</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Sickle cell anemia</bold>
</p>
        <p>Treatment options for sickle cell anemia&#x000a0;focus on symptom management, complication prevention, and enhancing overall quality of life. A blood transfusion may be initiated based on the rate of hemoglobin&#x000a0;decline and the patient's clinical condition, especially during aplastic crises characterized by low reticulocyte counts. An exchange transfusion may be performed in vaso-occlusive crises or severe complications, such as acute chest syndrome or stroke. This procedure involves gradually replacing the patient's blood with a donor or substitute, aiming&#x000a0;to decrease&#x000a0;sickle&#x000a0;cell count,&#x000a0;reduce blood viscosity,&#x000a0;enhance circulation, and&#x000a0;reduce&#x000a0;further complications.</p>
        <p>Hydroxyurea, oral medication,&#x000a0;is a viable option for&#x000a0;managing sickle cell anemia. Its mechanism involves&#x000a0;stimulating fetal hemoglobin production, thereby inhibiting the sickling of RBCs. Hydroxyurea effectively reduces the frequency and severity of sickle cell crises, decreases the need for transfusions, and improves overall symptoms and quality of life.</p>
        <p>
<bold>Platelet disorders</bold>
</p>
        <p>Patients with thrombocytopenia&#x000a0;and clinical evidence of bleeding&#x000a0;warrant&#x000a0;a platelet transfusion.&#x000a0;Those&#x000a0;with platelet counts below 10,000/&#x003bc;L face a risk&#x000a0;of spontaneous cerebral hemorrhage and thus&#x000a0;necessitate&#x000a0;prophylactic transfusion. For conditions like HUS and TTP, large-volume plasmapheresis with FFP replacement is the preferred treatment, often requiring daily sessions. Treatment&#x000a0;objectives include increasing platelet count, decreasing lactate dehydrogenase (LDH) levels, and reducing RBC fragments as positive indicators of treatment response. Complementary measures, such as high-dose glucocorticoids and antiplatelet agents like aspirin, are often employed alongside plasmapheresis in cases of inadequate response to plasmapheresis interventions such as splenectomy or immunosuppression may be considered.&#x000a0;</p>
        <p>Initial management of atypical hemolytic uremic syndrome (aHUS) involves supportive care, similar to the approach used for Shiga toxin-producing <italic toggle="yes">Escherichia coli</italic>&#x02013;associated HUS (STEC-HUS). However,&#x000a0;for patients with severe complement-mediated HUS, particularly those at risk of death or end-stage renal disease (ESRD), eculizumab, a humanized monoclonal antibody to C5, is recommended.&#x000a0;Emerging evidence&#x000a0;suggests that early initiation of eculizumab can improve renal and nonrenal recovery.</p>
        <p>The&#x000a0;primary objective in treating&#x000a0;ITP is to&#x000a0;maintain a safe platelet count&#x000a0;that&#x000a0;mitigates clinically significant bleeding, rather than normalizing platelet counts.&#x000a0;The bleeding risk occurs when the platelet counts&#x000a0;fall&#x000a0;below 10,000/&#x000b5;L. Immediate platelet transfusion is recommended for patients experiencing severe bleeding, such as intracranial or GI bleeding, and having a platelet count of less than 30,000/&#x003bc;L. In addition to platelet transfusion, specific therapies for ITP, including intravenous immune globulin (IVIG), glucocorticoids, and romiplostim, are commonly used.</p>
        <p>
<bold>Congenital bleeding disorders</bold>
</p>
        <p>Von Willebrand disease, characterized by deficient or defective von Willebrand factor, can be effectively managed using different approaches. Primary treatment options&#x000a0;include desmopressin (DDAVP), recombinant von Willebrand factor (rVWF), and von Willebrand factor/factor VIII (vWF/FVIII) concentrates. These treatments aim to replenish or enhance the function of von Willebrand factor, thereby mitigating bleeding episodes and improving overall clinical outcomes.</p>
        <p>Factor VIII and IX concentrates are employed to manage hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency), respectively. The dosage and administration of these concentrates&#x000a0;vary depending&#x000a0;on the site and severity of bleeding in each patient.&#x000a0;This tailored approach ensures effective control of bleeding episodes while minimizing the risk of complications associated with hemophilia.</p>
        <p>
<bold>Disseminated intravascular coagulation</bold>
</p>
        <p>The management of DIC primarily focuses on addressing the underlying cause to eliminate the stimulus for ongoing coagulation and thrombosis. Prophylactic transfusion of platelets and coagulation factors is not recommended when the platelet count remains above or equal to 10,000/&#x003bc;L.&#x000a0;However, treatment is warranted&#x000a0;in patients with severe bleeding,&#x000a0;those&#x000a0;at high risk for bleeding complications, or those requiring invasive procedures. Notably, antifibrinolytic agents, such as tranexamic acid (TXA), epsilon-aminocaproic acid (EACA), or aprotinin, are contraindicated in managing DIC.</p>
      </sec>
      <sec id="article-17530.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The following&#x000a0;conditions should not be overlooked when evaluating patients presenting with anemia.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Trauma
<list list-type="bullet"><list-item><p>Trauma or blood loss</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>GI bleed
<list list-type="bullet"><list-item><p>Noted&#x000a0;GI bleed</p></list-item><list-item><p>Nonsteroidal anti-inflammatory drug (NSAID) or corticosteroid use</p></list-item><list-item><p>Alcohol use</p></list-item><list-item><p>Cirrhosis</p></list-item><list-item><p>Anticoagulant use</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rupture of vascular aneurysm
<list list-type="bullet"><list-item><p>May present with sudden-onset tearing pain. Loss of consciousness may also occur.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Surgery
<list list-type="bullet"><list-item><p>Recent surgery&#x000a0;involving&#x000a0;moderate blood loss</p></list-item><list-item><p>History of bleeding disorders or excessive bruising</p></list-item><list-item><p>Use of antibiotics</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Menorrhagia
<list list-type="bullet"><list-item><p>Excessive menstrual bleeding lasting &#x0003e;7 days</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nutritional deficiencies/malnutrition
<list list-type="bullet"><list-item><p>Iron, vitamin B12, or folate deficiency&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Myelodysplastic syndrome
<list list-type="bullet"><list-item><p>Macrocytic anemia with leukopenia, macro-ovalocytes, and especially bilineage cytopenias</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Leukemia
<list list-type="bullet"><list-item><p>Acute leukemias present with pancytopenia and the presence of 20% blasts on peripheral smear</p></list-item><list-item><p>Chronic leukemias can cause&#x000a0;normocytic anemia</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Infiltration of bone marrow by malignancy
<list list-type="bullet"><list-item><p>weight loss, malaise, fevers, fatigue</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Drug toxicity
<list list-type="bullet"><list-item><p>Known or suspected ingestion of causative drug before the onset</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Anemia of chronic disease
<list list-type="bullet"><list-item><p>History of known chronic inflammatory, autoimmune, or infectious states</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic kidney disease or chronic liver disease&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pregnancy
<list list-type="bullet"><list-item><p>Most notable in the later stages, such as the third semester&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17530.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of acute anemia correlates with its severity, rate of development, and concurrent illnesses.<xref ref-type="bibr" rid="article-17530.r15">[15]</xref><xref ref-type="bibr" rid="article-17530.r16">[16]</xref><xref ref-type="bibr" rid="article-17530.r17">[17]</xref><xref ref-type="bibr" rid="article-17530.r18">[18]</xref><xref ref-type="bibr" rid="article-17530.r19">[19]</xref>&#x000a0;Typically, anemia&#x000a0;exacerbates a patient's&#x000a0;overall condition, adding further stress to the body and potentially&#x000a0;accelerating the progression of underlying diseases or conditions.&#x000a0;</p>
        <p>Time&#x000a0;is of the essence in managing acute anemia. Failure to promptly identify and address the underlying cause can have severe consequences, potentially resulting in a rapid deterioration of the patient's health. Therefore, timely intervention and appropriate management are paramount to mitigate adverse outcomes associated with acute anemia.&#x000a0;</p>
      </sec>
      <sec id="article-17530.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The most severe complication&#x000a0;of acute anemia arises&#x000a0;from&#x000a0;hypovolemic&#x000a0;shock&#x000a0;caused by significant&#x000a0;hemorrhage. Reduced blood volume can lead to tissue hypoxia, precipitating end-organ damage such as heart attack, heart failure, renal failure, acute hypoxic respiratory failure, or other manifestations of organ dysfunction.&#x000a0; &#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-17530.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>In the management of challenging-to-treat anemias, leukemia patients, or severe cases of ITP, TTP, or HUS, the expertise of a hematology/oncology specialist is essential. Their specialized knowledge and experience are crucial for accurately diagnosing and developing tailored treatment plans for these complex hematologic conditions.</p>
        <p>Consultation with a gastroenterologist is essential for GI bleeding cases. Their expertise allows for using&#x000a0;techniques&#x000a0;like&#x000a0;endoscopy to visualize and treat bleeding lesions or ulcers in the GI tract,&#x000a0;significantly enhancing the management&#x000a0;of GI bleeding.</p>
        <p>A surgeon's involvement is crucial in instances of trauma or vascular aneurysm rupture. They&#x000a0;possess the skill to execute&#x000a0;essential surgical interventions, control bleeding, repair damaged blood vessels, and&#x000a0;administer&#x000a0;appropriate surgical care to patients in critical conditions.</p>
      </sec>
      <sec id="article-17530.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Chronic anemia can manifest silently,&#x000a0;with the body gradually&#x000a0;adapting to lower RBC and hemoglobin levels. Conversely, acute anemia may present with more pronounced signs and symptoms,&#x000a0;explaining the underlying cause.&#x000a0;However, in acute scenarios, time becomes paramount&#x000a0;as healthcare practitioners must&#x000a0;promptly identify and address the cause to prevent potential complications.</p>
        <p>Collaboration and teamwork among healthcare staff are crucial when managing anemia. Equally important is the patient's cooperation and compliance.</p>
      </sec>
      <sec id="article-17530.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to keep in mind about&#x000a0;acute anemia are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute anemia&#x000a0;is a sudden&#x000a0;decline in RBC count,&#x000a0;typically precipitated by&#x000a0;hemolysis or acute hemorrhage.</p>
          </list-item>
          <list-item>
            <p>Acute anemia can result from various causes, including trauma, hemorrhage (such as GI bleeding or trauma-related bleeding), hemolysis (such as autoimmune hemolytic anemia or hemolytic transfusion reaction), and other acute conditions.</p>
          </list-item>
          <list-item>
            <p>Patients with acute anemia may present with symptoms such as weakness, fatigue, pallor, tachycardia, hypotension, shortness of breath, and, in severe cases, shock.</p>
          </list-item>
          <list-item>
            <p>In cases of acute anemia, it is crucial to prioritize the ABCs and initiate resuscitation as necessary.</p>
          </list-item>
          <list-item>
            <p>Promptly collect a blood sample for typing and cross-matching and conduct serial CBCs to closely monitor hemoglobin and hematocrit levels throughout the patient's care.</p>
          </list-item>
          <list-item>
            <p>The initial steps in management involve administering supplemental oxygen, establishing large-bore&#x000a0;intravenous access, initiating intravenous fluid resuscitation with crystalloid fluids, and applying direct pressure to any site of hemorrhage to control bleeding.</p>
          </list-item>
          <list-item>
            <p>Transfusion of pRBCs is indicated when&#x000a0;hemoglobin&#x000a0;levels drop below 7 g/dL or based on clinical judgment. Typically, each unit of pRBCs increases the hematocrit by about 3 percentage points and the&#x000a0;hemoglobin level by 1 g/dL.</p>
          </list-item>
          <list-item>
            <p>Complications of acute anemia include hypovolemic shock, tissue hypoxia, end-organ damage, and death if left untreated or inadequately managed. Early recognition and intervention are crucial to prevent adverse outcomes.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17530.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>In the realm of acute anemia management, various healthcare professionals must collaborate effectively to ensure patient-centered care, optimal outcomes, and safety. Physicians, advanced practitioners, nurses, pharmacists, and other team members should possess proficient skills in recognizing anemia's signs and symptoms, conducting diagnostic tests, and implementing appropriate treatment strategies promptly.</p>
        <p>Responsibilities are distributed among team members, with clear communication channels established to facilitate interprofessional collaboration and care coordination. Regular communication updates, shared decision-making, and mutual respect among team members enhance patient safety and contribute to improved outcomes.</p>
        <p>The interprofessional&#x000a0;team is pivotal in managing acute anemia&#x000a0;to&#x000a0;improve patient outcomes.&#x000a0;Education&#x000a0;is a&#x000a0;vital component of the care plan, emphasizing patient adherence&#x000a0;to prescribed&#x000a0;medications like iron supplements and steroids, avoidance of known triggers such as alcohol consumption and NSAID use, and&#x000a0;comprehension of&#x000a0;the underlying cause of the anemia to prevent future episodes.</p>
      </sec>
      <sec id="article-17530.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17530&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17530">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/acute-anemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17530">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17530/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17530">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17530.s18">
        <title>References</title>
        <ref id="article-17530.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vieth</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Anemia.</article-title>
            <source>Hematol Oncol Clin North Am</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>1045</fpage>
            <page-range>1045-1060</page-range>
            <pub-id pub-id-type="pmid">29078923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cappellini</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Motta</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Anemia in Clinical Practice-Definition and Classification: Does Hemoglobin Change With Aging?</article-title>
            <source>Semin Hematol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>261</fpage>
            <page-range>261-9</page-range>
            <pub-id pub-id-type="pmid">26404438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perrotta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Mohandas</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Hereditary spherocytosis.</article-title>
            <source>Lancet</source>
            <year>2008</year>
            <month>Oct</month>
            <day>18</day>
            <volume>372</volume>
            <issue>9647</issue>
            <fpage>1411</fpage>
            <page-range>1411-26</page-range>
            <pub-id pub-id-type="pmid">18940465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iolascon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Avvisati</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Piscopo</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Hereditary spherocytosis.</article-title>
            <source>Transfus Clin Biol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>138</fpage>
            <page-range>138-42</page-range>
            <pub-id pub-id-type="pmid">20655264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niss</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Chonat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dagaonkar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Almansoori</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Kerr</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>ZR</given-names>
              </name>
              <name>
                <surname>McGann</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Quarmyne</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Risinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kalfa</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis.</article-title>
            <source>Blood Cells Mol Dis</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>61</volume>
            <fpage>4</fpage>
            <page-range>4-9</page-range>
            <pub-id pub-id-type="pmid">27667160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joly</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Coppo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Veyradier</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Thrombotic thrombocytopenic purpura.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>May</month>
            <day>25</day>
            <volume>129</volume>
            <issue>21</issue>
            <fpage>2836</fpage>
            <page-range>2836-2846</page-range>
            <pub-id pub-id-type="pmid">28416507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Webster</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schnitzler</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Hemolytic uremic syndrome.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2014</year>
            <volume>120</volume>
            <fpage>1113</fpage>
            <page-range>1113-23</page-range>
            <pub-id pub-id-type="pmid">24365375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Picard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Burtey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bornet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Curti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Montana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vanelle</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome.</article-title>
            <source>Pathol Biol (Paris)</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>136</fpage>
            <page-range>136-43</page-range>
            <pub-id pub-id-type="pmid">25845294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of disseminated intravascular coagulation.</article-title>
            <source>Int J Lab Hematol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>228</fpage>
            <page-range>228-36</page-range>
            <pub-id pub-id-type="pmid">24750668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liebman</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Weitz</surname>
                <given-names>IC</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune Hemolytic Anemia.</article-title>
            <source>Med Clin North Am</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>101</volume>
            <issue>2</issue>
            <fpage>351</fpage>
            <page-range>351-359</page-range>
            <pub-id pub-id-type="pmid">28189175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lv</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Hypersplenism: History and current status.</article-title>
            <source>Exp Ther Med</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>2377</fpage>
            <page-range>2377-2382</page-range>
            <pub-id pub-id-type="pmid">27703501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nissenson</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Wade</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goodnough</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dubois</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Economic burden of anemia in an insured population.</article-title>
            <source>J Manag Care Pharm</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>565</fpage>
            <page-range>565-74</page-range>
            <pub-id pub-id-type="pmid">16137214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>The Lancet Haematology</surname>
              </name>
            </person-group>
            <article-title>Updates on blood transfusion guidelines.</article-title>
            <source>Lancet Haematol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>3</volume>
            <issue>12</issue>
            <fpage>e547</fpage>
            <pub-id pub-id-type="pmid">27890071</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Napolitano</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Anemia and Red Blood Cell Transfusion: Advances in Critical Care.</article-title>
            <source>Crit Care Clin</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>345</fpage>
            <page-range>345-364</page-range>
            <pub-id pub-id-type="pmid">28284299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jim&#x000e9;nez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Escobar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>C&#x000e9;sar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Avello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sueiro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yusen</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Association of anaemia and mortality in patients with acute pulmonary embolism.</article-title>
            <source>Thromb Haemost</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>102</volume>
            <issue>1</issue>
            <fpage>153</fpage>
            <page-range>153-8</page-range>
            <pub-id pub-id-type="pmid">19572080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Migone de Amicis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chivite</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Corbella</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Cappellini</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Formiga</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Anemia is a mortality prognostic factor in patients initially hospitalized for acute heart failure.</article-title>
            <source>Intern Emerg Med</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>749</fpage>
            <page-range>749-756</page-range>
            <pub-id pub-id-type="pmid">28233161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kikuchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Inagaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shinagawa</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Five-year survival of older people with anemia: variation with hemoglobin concentration.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>49</volume>
            <issue>9</issue>
            <fpage>1226</fpage>
            <page-range>1226-8</page-range>
            <pub-id pub-id-type="pmid">11559383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>du Cheyron</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Parienti</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Fekih-Hassen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Daubin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Charbonneau</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Impact of anemia on outcome in critically ill patients with severe acute renal failure.</article-title>
            <source>Intensive Care Med</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>11</issue>
            <fpage>1529</fpage>
            <page-range>1529-36</page-range>
            <pub-id pub-id-type="pmid">16205892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17530.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cai</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SQ</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>XX</given-names>
              </name>
            </person-group>
            <article-title>The effect of anemia on the severity and prognosis of patients with acute pancreatitis: A single-center retrospective study.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2022</year>
            <month>Dec</month>
            <day>30</day>
            <volume>101</volume>
            <issue>52</issue>
            <fpage>e32501</fpage>
            <pub-id pub-id-type="pmid">36596024</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
